Multiple myeloma (MM) is a cancer of plasma cells that has been extensively studied in
recent years, with researchers increasingly focusing on the role of microRNAs (miRNAs) in …

Significant progress has been achieved in the realm of therapeutic interventions for multiple
myeloma (MM), leading to transformative shifts in its clinical management. While …

Extracellular vesicles (EVs) are lipid bilayer nanovesicles released from living or apoptotic
cells that can transport DNA, RNA, protein, and lipid cargo. EVs play critical roles in cell–cell …

Introduction Multiple myeloma (MM) is still an incurable plasma cell malignancy. The efficacy
of immunotherapy on MM remains unsatisfactory, and the underlying molecular mechanisms …

Obesity and obesogenic behaviors are positively associated with both monoclonal
gammopathy of unknown significance (MGUS) and multiple myeloma (MM). As the only …

Backgrounds Decreased cytotoxicity of natural killer (NK) cells has been shown in multiple
myeloma (MM). However, the underlying molecular mechanisms remain unclear. Here, by …

Multiple myeloma is a cancer of bone marrow plasma cells that represents approximately
10% of hematologic malignancies. Though it is typically incurable, a remarkable suite of new …

Since multiple myeloma (MM) remains a cureless malignancy of plasma cells to date, it
becomes imperative to develop novel drugs and therapeutic targets for MM. We screened a …

The assessment of the cancer mutational profile is crucial for patient management,
stratification, and therapeutic decisions. At present, in hematological malignancies with a …

Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone
marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The …